Skip to main content

Specialty Pharmacy

  • CVS' Blue Cross and Blue Shield FEP specialty pharma contract expires at year end

    WOONSOCKET, R.I. — CVS Health’s contract to provide specialty pharmacy services for the Blue Cross and Blue Shield Federal Employee Program (FEP) will end at the end of 2017.

    “Given that the contract expires at year end, the loss of this contract does not affect the company’s 2017 financial results. The loss of this specialty pharmacy contract, which is expected to generate revenues of approximately $2.8 billion in 2017, is not expected to have a material impact on the company’s operating profit in 2018,” CVS wrote in a statement.

  • Actinium names long-time Johnson & Johnson exec to board of directors

    NEW YORK — Actinium Pharmaceuticals appointed Dr. Ajit Shetty to its board of directors. Dr. Shetty is a pharmaceutical industry executive with 36 years of experience at Johnson & Johnson and its subsidiary Janssen. Most recently Dr. Shetty served as the Head of Enterprise Supply Chain at J&J where he was responsible for the transformation and optimization of J&J’s global supply chain.

  • AbbVie joins Avatar Research Program

    NORTH CHICAGO, Ill. — AbbVie has joined the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program.

  • Former GPhA chairman named Impax’s president and CEO

    HAYWARD, Calif. — Impax Laboratories named Paul M. Bisaro its president and CEO, as well as the company’s board of directors.

    Bisaro succeeds J. Kevin Buchi, who has served as interim president and CEO since December. Bisaro, 56, has 25 years of generic and branded pharmaceutical experience. He previously served as executive chairman of Allergan, and president, CEO and chairman of the board of Actavis.

  • Cota expands Novartis agreement

    NEW YORK — Cota Healthcare inked a multi-year collaboration agreement with Novartis to help improve clinical and cost outcomes for breast cancer patients.

  • Bartell Drugs introduces specialty pharmacy service

    SEATTLE — Bartell Drugs introduced a specialty pharmacy service at all of its 65 Washington State locations.

    Some of the difficult-to-treat conditions may include cancer, hepatitis B and C, HIV, rheumatoid arthritis and a host of other medical conditions requiring very specialized medications and therapy regimens.

    “Being diagnosed and entering treatment can be overwhelming,” states Bartell’s Clinical Programs Manager, Christina Ree. “Our Specialty Pharmacy program helps take the fear out of the process and replaces it with confidence.”

  • Diplomat to dispense Kisqali

    FLINT, Mich. — Diplomat on Thursday announced availability of a new top-line treatment for metastatic breast cancer. The specialty pharmacy will dispense Kisqali, which was recently approved by the Food and Drug Administration. 
     
    Kisqali is a once-daily oral therapy for postmenopausal women with advanced of metastatic breast cancer that’s hormone-receptor positive and negative for human epidermal growth factor receptor 2. It’s meant to be used in combination with an aromatase inhibitor. 
     

  • Studies: Esbriet can improve life expectancies for idiopathic pulmonary fibrosis patients

    ALEXANDRIA, Va. — Pirfenidone (Esbriet) can improve life expectancy compared with best supportive care and lower the risk of lung function decline for patients with idiopathic pulmonary fibrosis, an irreversible and unpredictable disease of unknown etiology that makes breathing difficult and causes permanent scarring damage to the lungs, according to two studies published in the March issue of the Journal of Managed Care & Specialty Pharmacy.

X
This ad will auto-close in 10 seconds